Los Angeles Capital Management LLC bought a new stake in G1 Therapeutics, Inc. (NASDAQ:GTHX – Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 20,986 shares of the company’s stock, valued at approximately $48,000.
Other hedge funds have also made changes to their positions in the company. Rhumbline Advisers raised its stake in shares of G1 Therapeutics by 5,136.0% during the second quarter. Rhumbline Advisers now owns 50,632 shares of the company’s stock worth $115,000 after purchasing an additional 49,665 shares during the last quarter. Panagora Asset Management Inc. acquired a new stake in shares of G1 Therapeutics in the 2nd quarter valued at approximately $404,000. Bank of New York Mellon Corp acquired a new stake in G1 Therapeutics in the second quarter valued at $304,000. SG Americas Securities LLC boosted its position in shares of G1 Therapeutics by 248.1% during the 2nd quarter. SG Americas Securities LLC now owns 47,124 shares of the company’s stock worth $107,000 after purchasing an additional 33,588 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in G1 Therapeutics by 20.7% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,858 shares of the company’s stock worth $1,632,000 after buying an additional 64,790 shares in the last quarter. Institutional investors and hedge funds own 24.21% of the company’s stock.
G1 Therapeutics Price Performance
G1 Therapeutics stock opened at $7.15 on Tuesday. The stock has a market capitalization of $378.16 million, a P/E ratio of -11.53 and a beta of 1.66. G1 Therapeutics, Inc. has a 12-month low of $1.08 and a 12-month high of $7.19. The company has a debt-to-equity ratio of 1.34, a current ratio of 2.48 and a quick ratio of 2.12. The firm’s 50-day moving average is $5.66 and its two-hundred day moving average is $4.39.
Analyst Upgrades and Downgrades
GTHX has been the topic of a number of research reports. Needham & Company LLC restated a “hold” rating on shares of G1 Therapeutics in a report on Wednesday, August 7th. Wedbush downgraded G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright cut G1 Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 8th.
View Our Latest Stock Analysis on GTHX
About G1 Therapeutics
G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.
Featured Stories
- Five stocks we like better than G1 Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- What does consumer price index measure?
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.